Design of a Phase IIb, Randomized, Controlled, Double-Blind, Multi-Centre Study to Evaluate the Efficacy, Safety, and Immunogenicity of the GMZ2 Candidate Malaria Vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese Children Aged 12-60 Months

Malaria Journal - United Kingdom
doi 10.1186/1475-2875-9-s2-p26

Related search